Current Clinical PracticeFour Difficult Thyroid Cancer Cases: Incorporating Medical Therapies☆
Section snippets
Case No. 1
A 73-year-old male alcoholic patient with chronic obstructive pulmonary disease (COPD), obesity, and diabetes is evaluated in the intensive care unit for an enlarging neck mass. He was intubated for airway protection after he presented with syncope and hypoxia (ie, pickwickian syndrome in the setting of an enlarging neck mass). An ultrasound of the neck revealed a 6-cm heterogeneously cystic mass with enlarged locoregional bilateral cervical lymph nodes. The neck mass was biopsied and confirmed
Conclusions
This case series presented several opportunities for medical therapies to concurrently enhance the surgical management of difficult thyroid cancer scenarios. Specifically, case discussions focused on the evidence for various medical therapies (ie, cytotoxic chemotherapy, targeted therapy, and hormonal modulations). Treatment paradigms in thyroid cancers are shifting to incorporate new medical modalities of care. These paradigmatic changes should focus on how novel therapies will enhance the
REFERENCES (56)
- et al.
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Lancet
(2014) - et al.
Management of locally invasive well-differentiated thyroid cancer
Surg Oncol Clin North Am
(2008) - et al.
Combination adriamycin and radiation therapy for locally advanced carcinoma of the thyroid gland
Int J Radiat Oncol Biol Phys
(1983) - et al.
Segmental laryngotracheal and tracheal resection for invasive thyroid carcinoma
Ann Thorac Surg
(2007) - et al.
Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma
Biomed Pharmacother
(2008) - et al.
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
Lancet. Oncology
(2012) - et al.
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
Lancet Oncol
(2010) A phase 3 multicenter double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (DTC)
(2014)- et al.
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial
J Clin Oncol
(2012) - et al.
Cabozantinib in progressive medullary thyroid cancer
J Clin Oncol
(2013)
Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma
Expert Rev Anticancer Ther
Neoadjuvant chemotherapy in 16 patients with locally advanced papillary thyroid carcinoma
Thyroid
Clinical trial of weekly paclitaxel chemotherapy for papillary thyroid carcinoma with squamous cell carcinoma component
Endocr J
Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group
Cancer
A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma
Cancer
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma
J Clin Endocrinol Metab
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer
N Engl J Med
The management of thyroid carcinoma invading the larynx or trachea
Laryngoscope
Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas
Clin Cancer Res
Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib
J Clin Endocrinol Metab
Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation
Thyroid
Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer
J Clin Endocrinol Metab
Surgical management of laryngeal invasion by papillary thyroid carcinoma: a retrospective analysis
Thyroid
Medical management of metastatic medullary thyroid cancer
Cancer
Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide
Clin Endocrinol
Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma
Clin Endocrinol
Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon
Acta Oncol
Depicting medullary thyroid cancer recurrence: the past and the future of nuclear medicine imaging
Int J Endocrinol Metab
Cited by (0)
- ☆
Conflicts of interest: none.